Key result
The ACE DD genotype was associated with a decreased risk of hepatocellular carcinoma compared to I allele carriers.
Why the study?
Does the ACE I/D or eNOS 4a/4b gene polymorphism affect the risk of developing hepatocellular carcinoma in a Chinese population?
Case-Control (n=677)
No
Does the ACE I/D or eNOS 4a/4b gene polymorphism affect the risk of developing hepatocellular carcinoma in a Chinese population?
Answers are grounded in this paper and cite their sources.
The ACE I/D polymorphism, specifically the D allele and DD genotype, is associated with a decreased risk of hepatocellular carcinoma in the Chinese population.
Growing evidence suggests that the angiotensin-converting enzyme (ACE) and endothelial nitric oxide synthase (eNOS) genes are associated with risk in a wide range of cancers. The objective of this study was to examine whether two DNA polymorphisms at the ACE insertion/deletion (I/D) and the variable number of tandem repeats in NOS intron 4 (4a/4b) were linked to the risk of developing hepatocellular carcinoma (HCC) in a Chinese population. The polymorphisms at ACE I/D and eNOS 4a/4b were genotyped in 293 HCC patients and 384 healthy control subjects using polymerase chain reaction. The frequencies of the D allele (p=0.003, OR=0.72, 95% CI=0.58–0.90) in the ACE gene of HCC patients were significantly different from the healthy controls, and a significantly decreased HCC risk was associated with the DD genotype in both the recessive (p<0.001, OR=0.19, 95% CI=0.11–0.34) and codominant models (p<0.001, OR=0.26, 95% CI=0.14–0.48). This study provided evidence that the ACE I/D polymorphism is associated with HCC, indicating that the ACE I/D polymorphism contributes to HCC progression in the Chinese population. Insertion/deletion polymorphisms in the ACE gene and NOS-3 intron tandem repeats were studied to determine if there were a risk associated with these alleles in patients with hepatocellular carcinoma in China. Strong evidence was provided that the D allele and homozygous DD contribute to progression of HCC.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2013) conducted a case-control in Hepatocellular Carcinoma (n=677). ACE DD genotype vs. ACE II/ID genotypes (I allele carriers) was evaluated on Hepatocellular carcinoma risk (OR 0.19, 95% CI 0.11-0.34, p=<0.001). The ACE DD genotype was associated with a decreased risk of hepatocellular carcinoma compared to I allele carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: